½ÃÀ庸°í¼­
»óǰÄÚµå
1570943

Á¾¾ç±«»çÀÎÀÚ ÀúÇØÁ¦ ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®°ú ¿¹Ãø(2024-2032³â)

Tumor Necrosis Factor Inhibitor Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 260 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Á¾¾ç±«»çÀÎÀÚ(TNF) ÀúÇØÁ¦ ½ÃÀåÀº 2023³â¿¡ 413¾ï ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â CAGR 2.2%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ½ÃÀåÀÇ ¼ºÀåÀº °Ç¼±, ·ù¸¶Æ¼½º °üÀý¿°, ¿°Áõ¼ºÀåÁúȯ°ú °°Àº ÀÚ°¡¸é¿ªÁúȯÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áúȯ¿¡ ´ëÇÑ Àνİú Áø´Ü ´É·ÂÀÌ Çâ»óµÊ¿¡ µû¶ó È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, TNF ¾ïÁ¦Á¦´Â ¸¸¼º ¿°Áõ¼º ÁúȯÀÇ Áõ»ó Á¶Àý¿¡ È¿°úÀûÀÎ °ÍÀ¸·Î ¾Ë·ÁÁ® Ä¡·á ÇÁ·ÎÅäÄÝÀÇ Áß¿äÇÑ ÄÄÆ÷³ÍÆ®·Î ÀÚ¸® Àâ°í ÀÖ½À´Ï´Ù.

Á¾¾ç±«»çÀÎÀÚ ¾ïÁ¦Á¦ ½ÃÀåÀº ¾à¹° À¯Çüº°·Î ¼¿Æ®¸®ÁÖ¸¿ Æä°ñ, ¾Æ´Þ¸®¹«¸¿, ÀÎÇø¯½Ã¸¿, ¿¡Å¸³Ê¼ÁÆ®, °ñ¸®¹«¸¿À¸·Î ºÐ·ùµÇ¸ç, 2023³â¿¡´Â ¾Æ´Þ¸®¹«¸¿ ºÎ¹®ÀÌ ½ÃÀåÀ» ÁÖµµÇÏ¿© 242¾ï ´Þ·¯ ±Ô¸ð·Î Æò°¡µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¾¾ç±«»çÀÎÀÚ(TNF)¿¡ ÃÊÁ¡À» ¸ÂÃá ´ÜŬ·Ð Ç×üÀÎ ¾Æ´Þ¸®¹«¸¿Àº ±¤¹üÀ§ÇÑ È¿´É, ¿ì¼öÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏ, ´Ù¾çÇÑ ÀÚ°¡¸é¿ªÁúȯ¿¡ ´ëÇÑ »ç¿ëÀ¸·Î TNF ¾ïÁ¦Á¦ ºÐ¾ß¿¡¼­ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î Á¦Çü°ú Àü´Þ ¹æ¹ýÀÇ Áö¼ÓÀûÀÎ °³¹ß·Î ½ÃÀå¿¡¼­ÀÇ ÀÔÁö¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù.

ÀûÀÀÁõº°·Î Á¾¾ç±«»çÀÎÀÚ ¾ïÁ¦Á¦ ½ÃÀåÀº È­³ó¼º ¶¡»ù¿°, ·ù¸¶Æ¼½º °üÀý¿°, ·ù¸¶Æ¼½º °üÀý¿°, °Ç¼±, °Ç¼±, Å©·Ðº´, °­Á÷¼º ôÃß¿°, ±Ë¾ç¼º ´ëÀå¿°, û¼Ò³â Ư¹ß¼º °üÀý¿° ¹× ±âŸ ÁúȯÀ» Æ÷ÇÔÇϸç, 2023³â ·ù¸¶Æ¼½º °üÀý¿° ºÐ¾ß°¡ 42.0%ÀÇ Á¡À¯À²·Î ½ÃÀåÀ» ÁÖµµÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ·ù¸¶Æ¼½º °üÀý¿°(RA)Àº ÁÖ·Î °üÀý¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¸¸¼º ¿°Áõ¼º ÁúȯÀ¸·Î ÅëÁõ, ºÎÁ¾, °üÀý ¼Õ»óÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á¸¦ ¿øÇϴ ȯÀÚ°¡ ¸¹À¸¸ç, RAÀÇ À¯º´·ü Áõ°¡¿Í ´õºÒ¾î RA¿¡ ´ëÇÑ Àνİú Áø´ÜÀ²ÀÌ ³ô¾ÆÁö¸é¼­ RA Ä¡·á¿¡¼­ TNF ¾ïÁ¦Á¦¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

2023³â ºÏ¹ÌÀÇ ¸ÅÃâÀº 170¾ï ´Þ·¯¿¡ ´ÞÇϰí, ¼¼°è Á¾¾ç±«»çÀÎÀÚ ¾ïÁ¦Á¦ ½ÃÀåÀ» ÁÖµµÇß½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ¸®´õ½ÊÀº Çõ½ÅÀûÀÎ TNF ¾ïÁ¦Á¦ °³¹ßÀ» ¼±µµÇÏ´Â ¼±µµÀûÀÎ Á¦¾à»ç¿Í ¹ÙÀÌ¿À Á¦¾à»ç°¡ Á¸ÀçÇϹǷΠ°¡´ÉÇß½À´Ï´Ù. ºÏ¹ÌÀÇ °­·ÂÇÑ ÀÇ·á ½Ã½ºÅÛ°ú Àß È®¸³µÈ ±ÔÁ¦ °æ·Î°¡ °áÇÕµÇ¾î »õ·Î¿î Ä¡·á¹ýÀÇ ºü¸¥ ½ÃÀå ÁøÀÔ°ú ¼ö¿ëÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ȯÀÚµéÀÇ ³ôÀº Àνİú ÃÖ÷´Ü Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ Á¢±Ù¼ºÀº ¼¼°è TNF ¾ïÁ¦Á¦ ½ÃÀå¿¡¼­ ºÏ¹ÌÀÇ ¿ìÀ§¸¦ È®°íÈ÷ Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • ¿¡ÄڽýºÅÛ ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
      • ÀÚ°¡¸é¿ªÁúȯÀÇ Áõ°¡
      • Ä¡·á ÀûÀÀÀÇ È®´ë
      • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿Í ÀǾàǰ °³¹ßÀÇ Áøº¸
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ© & °úÁ¦
      • Ä¡·áºñÀÇ »ó½Â
      • ºÎÀÛ¿ë°ú ¾ÈÀü¼º¿¡ ´ëÇÑ ¿ì·Á
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±ÔÁ¦ »óȲ
  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ƯÇ㠺м®
  • PorterÀÇ »ê¾÷ ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ

  • ¼­·Ð
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« ´ë½Ãº¸µå

Á¦5Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ¾àÁ¦ Ŭ·¡½ºº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Adalimumab
    • ºê·£µå
    • ¹ÙÀÌ¿À½Ã¹Ð·¯
  • Etanercept
    • ºê·£µå
    • ¹ÙÀÌ¿À½Ã¹Ð·¯
  • Infliximab
    • ºê·£µå
    • ¹ÙÀÌ¿À½Ã¹Ð·¯
  • Golimumab
  • Certolizumab pegol

Á¦6Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : ÀûÀÀÁõº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ·ù¸¶Æ¼½º °üÀý¿°
  • °Ç¼±
  • °Ç¼±¼º °üÀý¿°
  • Å©·Ðº´
  • ±Ë¾ç¼º ´ëÀå¿°
  • °­Á÷¼º ôÃß¿°
  • ¼Ò¾ÆÆ¯¹ß¼º°üÀý¿°
  • È­³ó¼ºÇѼ±¿°
  • ±âŸ ÀûÀÀÁõ

Á¦7Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Åõ¿© °æ·Îº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ÇÇÇÏ ÁÖ»ç
  • Á¤¸ÆÁÖ»ç

Á¦8Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : À¯Åë ä³Îº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦9Àå ½ÃÀå Ã߻ꡤ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ³×´ú¶õµå
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå ±â¾÷ °³¿ä

  • AbbVie Inc.
  • Amgen Inc.
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Bio-Thera Solutions, Ltd.
  • Janssen Biotech, Inc.
  • Merck and Co., Inc.
  • Pfizer Inc.
  • Samsung Bioepis Co., Ltd.
  • Sandoz Group AG
  • UCB, Inc.
KSA 24.10.30

The Global Tumor Necrosis Factor (TNF) Inhibitor Drugs Market was valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from 2024-2032. The market's growth is largely attributed to the increasing incidence of autoimmune diseases such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease. As awareness and diagnostic capabilities for these conditions improve, the demand for effective treatment options has risen significantly. TNF inhibitors, known for their efficacy in controlling symptoms of chronic inflammatory diseases, have become a key component in treatment protocols.

The overall tumor necrosis factor inhibitor drugs industry is classified based on the drug class, indication, route of administration, distribution channel, and region.

The tumor necrosis factor inhibitor drugs market is categorized by drug class into certolizumab pegol, adalimumab, infliximab, etanercept, and golimumab. In 2023, the adalimumab segment led the market, commanding a valuation of USD 24.2 billion. Adalimumab, a monoclonal antibody with a focus on tumor necrosis factor (TNF), boasts a significant market share in the TNF inhibitor drugs arena, thanks to its broad efficacy, commendable safety profile, and prevalent use across various autoimmune diseases. The continuous development of novel formulations and delivery methods bolsters its market presence.

Segmented by indication, the tumor necrosis factor inhibitor drugs market includes hidradenitis suppurativa, rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, ankylosing spondylitis, ulcerative colitis, juvenile idiopathic arthritis, and other conditions. In 2023, the rheumatoid arthritis segment led the market with a 42.0% share. Rheumatoid arthritis (RA) is a chronic inflammatory disorder primarily impacting joints, leading to pain, swelling, and potential joint damage, resulting in a significant patient population seeking effective treatment. The rising prevalence of RA, combined with heightened awareness and diagnostic rates, has spurred the demand for TNF inhibitors in RA treatment.

In 2023, North America led the global tumor necrosis factor inhibitor drugs market with revenues reaching USD 17 billion, and projections suggest it could hit USD 20 billion by 2032. The region's leadership is largely due to the presence of top-tier pharmaceutical and biopharmaceutical companies, which are at the forefront of developing innovative TNF inhibitors. North America's strong healthcare system, paired with established regulatory pathways, ensures swift market entry and acceptance of new therapies. Heightened patient awareness and access to cutting-edge treatment options solidify North America's dominant stance in the global TNF inhibitor drugs market.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of autoimmune diseases
      • 3.2.1.2 Expansion of therapeutic indications
      • 3.2.1.3 Advancements in biotechnology and drug development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of treatment
      • 3.2.2.2 Side effects and safety concerns
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Patent analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Adalimumab
    • 5.2.1 Branded
    • 5.2.2 Biosimilar
  • 5.3 Etanercept
    • 5.3.1 Branded
    • 5.3.2 Biosimilar
  • 5.4 Infliximab
    • 5.4.1 Branded
    • 5.4.2 Biosimilar
  • 5.5 Golimumab
  • 5.6 Certolizumab pegol

Chapter 6 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Rheumatoid arthritis
  • 6.3 Psoriasis
  • 6.4 Psoriatic arthritis
  • 6.5 Crohn's disease
  • 6.6 Ulcerative colitis
  • 6.7 Ankylosing spondylitis
  • 6.8 Juvenile idiopathic arthritis
  • 6.9 Hidradenitis suppurativa
  • 6.10 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Subcutaneous injection
  • 7.3 Intravenous injection

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospital pharmacies
  • 8.3 Retail pharmacies
  • 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 AbbVie Inc.
  • 10.2 Amgen Inc.
  • 10.3 Boehringer Ingelheim Pharmaceuticals, Inc.
  • 10.4 Bio-Thera Solutions, Ltd.
  • 10.5 Janssen Biotech, Inc.
  • 10.6 Merck and Co., Inc.
  • 10.7 Pfizer Inc.
  • 10.8 Samsung Bioepis Co., Ltd.
  • 10.9 Sandoz Group AG
  • 10.10 UCB, Inc.
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦